TY - JOUR
TI - Low IL-23 levels in peripheral blood and bone marrow at diagnosis of
acute leukemia in children increased with the elimination of leukemic
burden
AU - Zampogiannis, Archontis
AU - Piperi, Christina
AU - Baka, Margarita and
AU - Zoi, Iliana
AU - Papavassiliou, Athanasios G.
AU - Moschovi, Maria
JO - Journal of Cellular and Molecular Medicine
PY - 2021
VL - 25
TODO - 15
SP - 7426-7435
PB - Wiley
SN - 1582-1838, 1582-4934
TODO - 10.1111/jcmm.16772
TODO - acute leukemia; acute lymphoblastic leukemia; acute myeloid leukemia;
children; IL-23
TODO - IL-23 is an IL-12 cytokine family member with pleiotropic functions that
regulates tumour growth in various cancer types, exhibiting both
anti-tumorigenic and pro-tumorigenic properties. Preclinical studies
have shown a potential anti-leukemic action on childhood B-ALL cells.
The study involved 65 children with acute leukemia [59 patients with
acute lymphoblastic leukemia (ALL) and 6 patients with acute myeloid
leukemia (AML)] and 27 healthy controls. Using an enzyme-linked
immunosorbent assay, we aimed to determine the IL-23 levels in the
peripheral blood (PB) and bone marrow (BM) of patients at diagnosis and
at the end of the induction therapy (EIT). PB IL-23 levels were lower in
leukemia patients compared to the healthy controls. In all acute
leukemia patients, IL-23 levels were significantly lower at diagnosis
both in PB (P = .015) and in BM (P = .037) compared to the PB and BM
concentrations at the EIT. The same pattern was present in both
subgroups of ALL and AML patients. The high leukemic burden at diagnosis
was related with lower IL-23 levels, which were increased with the
disease remission. Considering the anti-leukemic potential of this
cytokine, the elevation of the IL-23 concentration at the disease
remission indicates a beneficial role of IL-23 in paediatric acute
leukemia.
ER -